Compugen Ltd
Compugen Ltd (CGEN) Covered Calls
Compugen Ltd trades in the Biotechnology industry with an IV Rank of 38.89%, average versus the past year. CGEN's highest covered call setup is the $5.00 strike expiring Mar 19, 2027, sorted by theoretical annualized return. It's 138.10% out of the money with 126 days to expiration, a 142.86% return until expiration, and a 413.83% theoretical annualized return. Across the setups shown, annualized returns run from 52.30% to 413.83% at strikes between $2.50 and $5.00, with 126 to 216 days to expiration, as of Nov 13, 2026.
Read more
Running CGEN covered calls helps you generate income from Compugen Ltd shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CGEN covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If CGEN stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CGEN covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CGEN covered call is worth writing.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.
| 2027-03-19 | 126 | 5.00 | 138.10 | 0.10 | 0.15 | 300.00 | 142.86 | 413.83 | -4.76 | +0.20 | 361 | 0.05 |
| 2027-03-19 | 126 | 2.50 | 19.05 | 0.30 | 0.50 | 70.00 | 33.33 | 96.56 | -14.29 | +0.52 | 1,252 | 0.20 |
| 2027-06-17 | 216 | 2.50 | 19.05 | 0.25 | 0.85 | 65.00 | 30.95 | 52.30 | -11.90 | +0.59 | 24 | 0.60 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank38.89% Moderate
- Market cap (M$)193
- 52 weeks high-37.04%
- 52 weeks low42.66%
- Analyst recommendationStrong Buy
1.00 - Target price$4.80
135.29% above the current stock price - Dividend—
- Payout ratio0.00%
- Earnings date2026-11-09
- P/E5.31
- Future P/E—
- EPS (ttm)0.38
- EPS growth next 5 years—
As of Nov 16, 2026